Literature DB >> 21182225

Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma.

Jing Zhao1, Bing-Yun Yu, Dao-Yuan Wang, Jin-E Yang.   

Abstract

AIM: to investigate the effect of the G-1666A polymorphism in the multidrug resistance related protein-1 (MRP1) on outcome of hepatocellular carcinoma (HCC).
METHODS: a cohort of 162 patients with surgically resected HCC who received no postsurgical treatment until relapse was studied. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism analysis. Electrophoretic mobility shift assay (EMSA) was used to evaluate the influence of the G-1666A polymorphism on the binding affinity of the MRP1 promoter with its putative transcription factors.
RESULTS: Kaplan-Meier analysis showed that patients with GG homologues had a reduced 4-year disease-free survival compared with those carrying at least one A allele (P = 0.011). Multivariate Cox regression analysis indicated that the -1666GG genotype represented an independent predictor of poorer disease-free survival [hazard ratio (HR) = 3.067, 95% confidence interval (CI): 1.587-5.952, P = 0.001], and this trend became worse in men (HR = 3.154, 95% CI: 1.604-6.201, P = 0.001). A similar association was also observed between 4-year overall survival and the polymorphism in men (HR = 3.342, 95% CI: 1.474-7.576, P = 0.004). Moreover, EMSA suggested that the G allele had a stronger binding affinity to nuclear proteins.
CONCLUSION: the MRP1 -1666GG genotype predicted a worse outcome and was an independent predictor of poor survival in patients with HCC from Southeast China.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21182225      PMCID: PMC3012574          DOI: 10.3748/wjg.v16.i48.6104

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  27 in total

1.  Prognosis in patients with hepatocellular carcinoma correlates to mutations of p53 and/or hMSH2 genes.

Authors:  Masatsugu Yano; Kiyohiro Hamatani; Hidetaka Eguchi; Yuko Hirai; Donald G MacPhee; Keizo Sugino; Kiyohiko Dohi; Toshiyuki Itamoto; Toshimasa Asahara
Journal:  Eur J Cancer       Date:  2007-03-12       Impact factor: 9.162

2.  Dendritic cells require multidrug resistance protein 1 (ABCC1) transporter activity for differentiation.

Authors:  Rieneke van de Ven; Mariska C de Jong; Anneke W Reurs; Antoinet J N Schoonderwoerd; Gerrit Jansen; Jan H Hooijberg; George L Scheffer; Tanja D de Gruijl; Rik J Scheper
Journal:  J Immunol       Date:  2006-05-01       Impact factor: 5.422

Review 3.  Transport of glutathione and glutathione conjugates by MRP1.

Authors:  Susan P C Cole; Roger G Deeley
Journal:  Trends Pharmacol Sci       Date:  2006-07-03       Impact factor: 14.819

4.  Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer.

Authors:  Hiroaki Obata; Tetsuro Yahata; Jinhua Quan; Masayuki Sekine; Kenichi Tanaka
Journal:  Anticancer Res       Date:  2006 May-Jun       Impact factor: 2.480

5.  ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1.

Authors:  J Renes; E G de Vries; E F Nienhuis; P L Jansen; M Müller
Journal:  Br J Pharmacol       Date:  1999-02       Impact factor: 8.739

Review 6.  A single nucleotide polymorphism in the p53 pathway interacts with gender, environmental stresses and tumor genetics to influence cancer in humans.

Authors:  G L Bond; A J Levine
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

Review 7.  Substrate recognition and transport by multidrug resistance protein 1 (ABCC1).

Authors:  Roger G Deeley; Susan P C Cole
Journal:  FEBS Lett       Date:  2005-12-21       Impact factor: 4.124

Review 8.  ABC multidrug transporters: structure, function and role in chemoresistance.

Authors:  Frances J Sharom
Journal:  Pharmacogenomics       Date:  2008-01       Impact factor: 2.533

9.  Large-scale analysis of the genetic and epigenetic alterations in hepatocellular carcinoma from Southeast China.

Authors:  Hang Su; Jing Zhao; Yujuan Xiong; Teng Xu; Fan Zhou; Yunfei Yuan; Ying Zhang; Shi-Mei Zhuang
Journal:  Mutat Res       Date:  2008-02-14       Impact factor: 2.433

10.  The t-PA -7351C>T enhancer polymorphism decreases Sp1 and Sp3 protein binding affinity and transcriptional responsiveness to retinoic acid.

Authors:  Anna Tjärnlund Wolf; Robert L Medcalf; Christina Jern
Journal:  Blood       Date:  2004-10-05       Impact factor: 22.113

View more
  8 in total

1.  Silencing MRP1-4 genes by RNA interference enhances sensitivity of human hepatoma cells to chemotherapy.

Authors:  Zheng Su; Gaojie Liu; Tingfeng Fang; Yang Wang; Huayao Zhang; Shanglin Yang; Jinxing Wei; Zejian Lv; Langping Tan; Jianping Liu
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

2.  Association of the human astrocyte elevated gene-1 promoter variants with susceptibility to hepatocellular carcinoma.

Authors:  Gholamreza Motalleb; Naghmeh Gholipour; Nader Mansour Samaei
Journal:  Med Oncol       Date:  2014-03-22       Impact factor: 3.064

3.  Association of Two Polymorphic Codons in P53 and ABCC1 Promoter with Prostate Cancer.

Authors:  Farinaz Behfarjam; Jalal Rostamzadeh; Mohammad Ali Zarei; Bahram Nikkhoo
Journal:  Iran J Biotechnol       Date:  2015-03       Impact factor: 1.671

Review 4.  Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application.

Authors:  Jiye Yin; Jianting Zhang
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2011-10

Review 5.  Effect of Liver Disease on Hepatic Transporter Expression and Function.

Authors:  Nilay Thakkar; Jason R Slizgi; Kim L R Brouwer
Journal:  J Pharm Sci       Date:  2017-04-30       Impact factor: 3.534

6.  Regulatory mechanism of ZNF139 in multi-drug resistance of gastric cancer cells.

Authors:  Yong Li; Bi-bo Tan; Qun Zhao; Li-qiao Fan; Yü Liu; Dong Wang
Journal:  Mol Biol Rep       Date:  2014-02-11       Impact factor: 2.316

Review 7.  The role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapy.

Authors:  Jose J G Marin; Maria J Monte; Alba G Blazquez; Rocio I R Macias; Maria A Serrano; Oscar Briz
Journal:  Acta Pharmacol Sin       Date:  2013-12-09       Impact factor: 6.150

Review 8.  Pharmacogenetics of hepatocellular carcinoma and cholangiocarcinoma.

Authors:  Marta Alonso-Peña; Anabel Sanchez-Martin; Paula Sanchon-Sanchez; Meraris Soto-Muñiz; Ricardo Espinosa-Escudero; Jose J G Marin
Journal:  Cancer Drug Resist       Date:  2019-09-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.